Breaking Through Bureaucracy: Can D.C. Embrace Evidence-Based Drug Policy?

May 21, 2024
Featuring: Senator Tom Daschle & Charlie Panfil

In this episode, Joe interviews two members of The Daschle Group: Founder and CEO, Senator Tom Daschle; and Public Policy Advisor, Charlie Panfil.

Subscribe Share

In this episode, Joe interviews two members of The Daschle Group: Founder and CEO, Senator Tom Daschle; and Public Policy Advisor, Charlie Panfil.

As Senator Daschle served in the House of Representatives for eight years (starting in 1978) and the Senate for 21, he was deep in the War on Drugs at its peak, and thankfully, as seen with so many of his constituents in recent years, the data and personal stories of so many healed people has broken through the propaganda and made him a strong advocate for psychedelic-assisted therapy. While minds are changing, and progress is happening before our eyes (the majority of substances the FDA is currently researching for psychiatric indications contain some form of psychedelic ingredient), government bureaucracy, a severe lack of communication between the FDA and DEA, and decades of lies are still massive roadblocks. How do we address all of this while advancing research?

They discuss:

  • The need to develop a partnership between the public and private sectors, mostly for the cost of treatments
  • The DEA’s place in all of this: If they’re essentially a law enforcement agency, why are they involved in the safety and efficacy of medical treatments?
  • The STATES Act, the Breakthrough Therapies Act, and how they can affect research
  • Why we need to move past relying on opioids, and instead, embrace a science-based drug policy

and more!

Links The PACT Act and your VA benefits The Chemistry of DOI S.5123 – Breakthrough Therapies Act

PT488 – The Cost of War: Veterans’ Mental Health and Government Responsibility, featuring: Matthew ‘Whiz’ Buckley STATES Act 2.0 Would Make the Federal Government More In Sync with the States and the People on Marijuana

The Summit on Breakthrough Therapies for Addiction

PPA: Psychedelics and Pain Association AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Senator Tom Daschle

In this Episode

Senator Tom Daschle

Senator Daschle has participated in the development and debate of almost every major public policy issue of the last four decades. In 1978, he was elected to the U.S. House of Representatives, where he served for eight years. In 1986, he was elected to the U.S. Senate and was chosen as Senate Democratic Leader in 1994. Senator Daschle is one of the longest serving Senate Democratic leaders in history and one of only two to serve twice as both Majority and Minority Leader. During his tenure, Senator Daschle navigated the senate through some of its most historic economic and national security challenges. In 2003, he chronicled some of these experiences in his book, Like No Other Time: The 107th Congress and the Two Years That Changed America Forever.

Since leaving the Senate, Senator Daschle has remained an active and learned voice among policymakers. In 2007, Senator Daschle joined with former Majority Leaders, George Mitchell, Bob Dole, and Howard Baker to create the Bipartisan Policy Center, an organization dedicated to finding common ground on some of the pressing public policy challenges of our time. Senator Daschle continues to be a sought after thought leader on multiple issues ranging from improving American health care to protecting democracy, including multiple leadership positions in prominent organizations: chair of the board of directors at the National Democratic Institute, chair of the board of directors at the Center for American Progress, democratic co-chair of the Coalition for Cannabis Policy, Education, and Regulation (CPEAR), and more. Senator Daschle has been recognized by The Hill as one of DC’s Top Lobbyists for the last several years.

Daschle Group socials: X / Linkedin

Charlie Panfil 2

Charlie Panfil

Charlie Panfil is a public policy advisor with The Daschle Group, and a public policy advisory of Baker Donelson. He works with The Daschle Group’s corporate and nonprofit clients on public health & biodefense, technology, cannabis, psychedelic medicine, veterans’ mental health, and critical minerals policy matters. As part of his work on psychedelic medicine policy, Charlie represents the Veteran Mental Health Leadership Coalition and Reason for Hope, previously represented the American Psychedelic Practitioners Association, and collaborates with advocates across the psychedelic medicine ecosystem. Charlie received his master’s degree in legislative affairs at the George Washington University Graduate School of Political Management, where he specialized in health care and energy policy issues, including writing his health care policy thesis on regulatory barriers for psychedelic medicine. He also graduated summa cum laude from GWU with his bachelor’s degree. He serves as the fundraising committee co-chair of the LGBTQ+ Victory Fund’s National Campaign Board and is a member of the Advocacy Association, the Government Relations Association, and Q Street.

Socials: X / Linkedin